COMT and Parkinson disease: The introduction of MAO inhibitors (preserve dopamine) and catechol-O-methyl-transferase (COMT) inhibitors (preserve levodopa) in PD treatment resulted in increased brain availability of levodopa and also reduced levodopa-induced dyskinesias due to the more controlled level of available dopamine [44].